DB
ATNM icon

Dmitry Balyasny’s Actinium Pharmaceuticals ATNM Stock Holding History

Dmitry Balyasny’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-352
Closed -$34K – 1262
2015
Q4 		$34K Sell
352
-18
-5% -$1.2K ﹤0.01% 1196
2015
Q3 		$20K Buy
+370
New +$24.7K ﹤0.01% 1113

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Dmitry Balyasny's ATNM Position: Q1 2016 in Review

Dmitry Balyasny sold out of Actinium Pharmaceuticals (ATNM) in Q1 2016, closing a stake of 352 shares — an estimated $34K sold.

Dmitry Balyasny first reported a position in ATNM in Q3 2015 and held it in 2 quarters. The position peaked at $34K in Q4 2015. 30 funds tracked by Wall St. Rank hold ATNM as of Q1 2016.

  • Dmitry Balyasny reported no remaining Actinium Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Dmitry Balyasny sold 352 Actinium Pharmaceuticals shares in Q1 2016, an estimated $34K.
  • Dmitry Balyasny first reported a position in Actinium Pharmaceuticals in Q3 2015 and held it in 2 quarters.
  • Dmitry Balyasny's Actinium Pharmaceuticals position peaked at $34K in Q4 2015.
  • 30 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2016.

Based on Balyasny Asset Management's 13F filing for Q1 2016, filed 16 May 2016.